The Capital Markets team advised the underwriting syndicate for Royalty Pharma’s (Nasdaq: RPRX) completed public offering of an aggregate $1.5 billion of senior unsecured notes.  BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and TD Securities (USA) LLC acted as book-running managers for the offering.  Additional underwriters included DNB Markets, Inc., SG Americas Securities, LLC, SMBC Nikko Securities America, Inc., U.S. Bancorp Investments, Inc., Academy Securities, Inc., AmeriVet Securities, Inc., Blaylock Van, LLC, Cabrera Capital Markets LLC, Drexel Hamilton, LLC, R. Seelaus & Co., LLC, Samuel A. Ramirez & Company, Inc., Siebert Williams Shank & Co., LLC and Tigress Financial Partners LLC.

Royalty Pharma, founded in 1996, has pioneered the royalty funding market and continued to innovate in life science funding. They are the global leader in biopharma royalty transactions, with a diverse portfolio of leading therapies. For more information, please visit.   

The Goodwin team was led by Ben Marsh, Cindy Navarro, Li Chang and Kaitlyn Buffaloe (Capital Markets); James Barri (Debt); Andrew Harrow, Ariel White-Tsimikalis and Estelle Candau (Capital Markets); Janet Andolina and Garrett Gaughan (Tax); Katie Leah and James Eggleston (Tax); Jason Wilcox and Guckaya Gozde (Global Trade); Kathleen Kean and Iris Zike (IPTS); Sarah Bock (Employment); Jacqueline Klosek (Cybersecurity) and Ettore Santucci (Opinions). 

For additional details on the offering, please read the pricing press release